These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 7865289)

  • 21. Therapeutic vaccine trails in Thailand.
    Churdboonchart V
    J HIV Ther; 2004 Sep; 9(3):57-9. PubMed ID: 15534562
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges and opportunities for development of an AIDS vaccine.
    Nabel GJ
    Nature; 2001 Apr; 410(6831):1002-7. PubMed ID: 11309631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of vaccine research and development: the human immunodeficiency virus (HIV).
    Girard MP; Osmanov SK; Kieny MP
    Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA.
    WHO/UNAIDS/IAVI International Expert Group
    AIDS; 2007 Feb; 21(4):539-46. PubMed ID: 17301582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human trials of experimental HIV vaccines.
    Burke DS
    AIDS; 1995; 9 Suppl A():S171-80. PubMed ID: 8819583
    [No Abstract]   [Full Text] [Related]  

  • 26. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers.
    Evans TG; Keefer MC; Weinhold KJ; Wolff M; Montefiori D; Gorse GJ; Graham BS; McElrath MJ; Clements-Mann ML; Mulligan MJ; Fast P; Walker MC; Excler JL; Duliege AM; Tartaglia J
    J Infect Dis; 1999 Aug; 180(2):290-8. PubMed ID: 10395842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [HIV/AIDS vaccines: heading for new vaccine approaches?].
    Girard MP
    Bull Soc Pathol Exot; 2008 Jun; 101(3):220-6. PubMed ID: 18681215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
    Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
    Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ethical elements in the development of vaccines against HIV/AIDS].
    Molina CN
    Sidahora; 2001 Oct; ():14-6. PubMed ID: 11776246
    [No Abstract]   [Full Text] [Related]  

  • 30. [BCG vaccination and development of an innovative vaccine for preventing vertical HIV transmission in Africa].
    Pontrelli G; Colizzi V
    Ig Sanita Pubbl; 2006; 62(2):189-99. PubMed ID: 17206189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Army HIV vaccine to undergo clinical trial as rival is halted.
    Check E
    Nature; 2002 Mar; 416(6876):6. PubMed ID: 11882860
    [No Abstract]   [Full Text] [Related]  

  • 32. Development of prophylactic AIDS vaccines: the current state of affairs.
    Hanke T
    Curr Opin Mol Ther; 2003 Feb; 5(1):25-32. PubMed ID: 12669467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. South African AIDS Vaccine Initiative launches phase I trial.
    Kresge KJ
    IAVI Rep; 2009; 13(4):19. PubMed ID: 20225578
    [No Abstract]   [Full Text] [Related]  

  • 34. Candidate HIV-1 gp140DeltaV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge.
    Bråve A; Hinkula J; Cafaro A; Eriksson LE; Srivastava IK; Magnani M; Ensoli B; Barnett SW; Wahren B; Rollman E
    Vaccine; 2007 Sep; 25(39-40):6882-90. PubMed ID: 17707956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccine study is enrolling.
    AIDS Patient Care STDS; 2005 Apr; 19(4):276-7. PubMed ID: 15920787
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Italy launches clinical trial for HIV vaccine.
    Nature; 2008 Jul; 454(7204):564. PubMed ID: 18668075
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers.
    Belshe RB; Stevens C; Gorse GJ; Buchbinder S; Weinhold K; Sheppard H; Stablein D; Self S; McNamara J; Frey S; Flores J; Excler JL; Klein M; Habib RE; Duliege AM; Harro C; Corey L; Keefer M; Mulligan M; Wright P; Celum C; Judson F; Mayer K; McKirnan D; Marmor M; Woody G;
    J Infect Dis; 2001 May; 183(9):1343-52. PubMed ID: 11294665
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV/AIDS. Hedged bet: an unusual AIDS vaccine trial.
    Cohen J
    Science; 2005 Aug; 309(5737):1003. PubMed ID: 16099960
    [No Abstract]   [Full Text] [Related]  

  • 40. How should the potency of HIV vaccine candidates be determined?
    Sheets R; Bean P
    Am Clin Lab; 2000; 19(8):23. PubMed ID: 11146989
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.